Skip to main content

Main menu

  • HOME
  • ARTICLES
    • Current Issue
    • Ahead of Print
    • Archives
    • Abstracts In Press
    • Special Issue Archive
    • Subject Collections
  • INFO FOR
    • Authors
    • Reviewers
    • Call For Papers
    • Subscribers
    • Advertisers
  • SUBMIT
    • Manuscript
    • Peer Review
  • ABOUT
    • The JABFM
    • The Editing Fellowship
    • Editorial Board
    • Indexing
    • Editors' Blog
  • CLASSIFIEDS
  • Other Publications
    • abfm

User menu

Search

  • Advanced search
American Board of Family Medicine
  • Other Publications
    • abfm
American Board of Family Medicine

American Board of Family Medicine

Advanced Search

  • HOME
  • ARTICLES
    • Current Issue
    • Ahead of Print
    • Archives
    • Abstracts In Press
    • Special Issue Archive
    • Subject Collections
  • INFO FOR
    • Authors
    • Reviewers
    • Call For Papers
    • Subscribers
    • Advertisers
  • SUBMIT
    • Manuscript
    • Peer Review
  • ABOUT
    • The JABFM
    • The Editing Fellowship
    • Editorial Board
    • Indexing
    • Editors' Blog
  • CLASSIFIEDS
  • JABFM on Bluesky
  • JABFM On Facebook
  • JABFM On Twitter
  • JABFM On YouTube
Brief ReportBrief Report

Dysrhythmias with Loperamide Used for Opioid Withdrawal

Nicki D. Vithalani, Christopher Heron, Ravishankar E. Rao, Anthony F. Cardell and Mark B. Stephens
The Journal of the American Board of Family Medicine November 2017, 30 (6) 832-834; DOI: https://doi.org/10.3122/jabfm.2017.06.170066
Nicki D. Vithalani
From the Penn State Health, State College, PA (NDV, CH, RER, MBS); Mount Nittany Physician Group, State College (AFC).
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christopher Heron
From the Penn State Health, State College, PA (NDV, CH, RER, MBS); Mount Nittany Physician Group, State College (AFC).
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ravishankar E. Rao
From the Penn State Health, State College, PA (NDV, CH, RER, MBS); Mount Nittany Physician Group, State College (AFC).
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anthony F. Cardell
From the Penn State Health, State College, PA (NDV, CH, RER, MBS); Mount Nittany Physician Group, State College (AFC).
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mark B. Stephens
From the Penn State Health, State College, PA (NDV, CH, RER, MBS); Mount Nittany Physician Group, State College (AFC).
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • References
  • Info & Metrics
  • PDF
Loading

Abstract

The antidiarrheal loperamide has had a recent, drastic increase in off-label use as an alternative treatment for symptoms of opioid withdrawal. The concept of this is easily discovered on the Internet and social media, where there are multiple blogs and forums promoting loperamide use at doses of 70 to 200 mg per day. Unfortunately, the serious side effects are not well recognized. Multiple cases of cardiac dysrhythmias contributing to death have been highlighted in recent literature. In November 2016, the US Food & Drug Administration released a statement highlighting the potential heart effects and risk of death with high doses of loperamide.1 This case regards a 22-year-old who took 200 mg of loperamide per day for 2 years as an alternative to methadone in her attempts to wean off heroin. Her subsequent spontaneous collapse, dysrhythmias, and acute hospital treatment are reviewed in detail as they were contradictory to standard therapy and required a multidisciplinary approach. Her outpatient management addressed the complex biological, psychological, and social aspects of her addiction.

  • Cardiovascular System
  • Community Medicine
  • Loperamide
  • Opioids
  • Patient Care
  • Primary Health Care
  • Substance Withdrawal Syndrome
  • Torsades de Pointes
  • Toxicity

The use of loperamide at high doses to avoid symptoms of heroin withdrawal has been steadily increasing since 2003. In a recent statement, the US Food & Drug Administration (FDA) addressed the association between high dose loperamide and adverse cardiac events including QT interval prolongation, torsades de pointes, ventricular arrhythmias, and cardiac arrest.1

Loperamide is available OTC for the symptomatic treatment of diarrhea. The approved daily dose is 8 mg per day. Loperamide at higher doses has found a reputation as an alternative to standard opioid withdrawal therapy. Information on this use is shared publicly through unregulated Internet forums and blogs without additional caution regarding adverse effects.2,3,4 Forty-eight documented cases of cardiac problems associated with loperamide misuse were reported to the FDA from 1976 to 2015, 10 of which were fatal.1

We report a case of loperamide used to alleviate symptoms of heroin withdrawal. The patient self medicated with up to 200 tablets a day of loperamide for 2 years. She presented to the Emergency Department in cardiac arrest. After successful resuscitation she had a prolonged QTc which progressed to torsades de pointes, which resolved with isoproterenol and transvenous pacing. Her dysrhythmias have not recurred after cessation of loperamide use.

Case Presentation

A 20-year-old female with a history of heroin use presented to the emergency department with a wide complex tachycardia following a brief syncopal episode. On questioning, she admitted to regularly taking large quantities of loperamide (Imodium) for the past several years as a cheaper alternative to methadone therapy. She had an ongoing history of substance use including heroin, tobacco, and alcohol. Citing a lack of insurance to cover standard therapy, she used the Internet to find alternate means of self detoxification. This led her to acquire and ingest large quantities (75 to 200 2-mg tablets) of loperamide daily over a 2-year span before her presentation.

Following a brief syncopal episode at home, Emergency Medical Services were activated by a friend who found the patient awake, but drowsy. On arrival, her initial rhythm strip showed a wide QRS and tachycardia with a prolonged QTc interval (Figure 1). During transport to the hospital, she became unresponsive, was pulseless, and her rhythm showed a wide-complex tachycardia. Cardiopulmonary resuscitation was initiated with return of her pulse.

Figure 1.
  • Download figure
  • Open in new tab
Figure 1.

Electrocardiogram in ambulance.

On arrival in the Emergency Department, her vital signs were normal. A complete physical examination and initial laboratory workup were also within normal limits. A 12-lead electrocardiogram showed a QTc interval of 766 ms (upper limit of normal, 440 ms for her age and sex). Poison control was contacted and magnesium and sodium bicarbonate were recommended to treat the prolonged QTc interval.

The patient was admitted to the intensive care unit and isoproterenol was added to treat the prolonged QTc interval. Despite this, she continued to have a wide-complex tachycardia with a markedly prolonged QTc interval (730 ms; Figure 2) which degenerated into torsades de pointes requiring repeated defibrillation. A temporary pacemaker was ultimately placed for overdrive pacing. This patient’s course was deemed a probable adverse drug reaction per the Naranjo Adverse Drug Reaction scale.5

Figure 2.
  • Download figure
  • Open in new tab
Figure 2.

Wide complex tachycardia progressing to torsades de pointes.

Over the next several days, her QTc interval gradually decreased to 462 ms with no further dysrhythmias. On discharge from the hospital, she was in good health and her electrocardiogram showed normal sinus rhythm. Since discharge, she has had no relapses of heroin or loperamide use.

Discussion

Loperamide is an FDA-approved antidiarrheal medication. It is currently on the World Health Organization list of essential travel medicines.6 It is available over the counter (OTC) or with prescription, and comes in tablet, capsule, and liquid formulations. A typical dosing schedule involves a 4-mg loading dose followed by 2 mg after each loose stool thereafter.7 Packaging recommends an 8-mg maximum daily dose for OTC preparations. Up to 16 mg/day is indicated by prescription.7 Loperamide exerts its clinical effects through the stimulation of gastrointestinal opiate receptors. This slows down intestinal peristalsis and decreases the number of stools. Loperamide is metabolized by a P-glycoprotein pump and does not cross the blood brain barrier. The most notable side effects include dry mouth, nausea, vomiting, dizziness, and constipation.8

Since 1976, the FDA has received formal reports of 48 cases of cardiovascular morbidity and mortality associated with loperamide use. In June 2016, the FDA released a statement regarding a warning about high-dose loperamide, and the association with a prolonged QTc.1 Other cases in the literature describe patients who also used loperamide at high doses for heroin withdrawal.9⇓⇓–12 Most of these cases reported ventricular arrhythmias and torsades de pointes, which were treated with isoproterenol and transvenous pacing, as other therapies were often unsuccessful. In surviving patients, dysrhythmias generally resolved after discontinuation of loperamide.9

Multiple unregulated blogs and online forums contain opinions and personal accounts of using loperamide as an off-label use for heroin withdrawal.2⇓–4 In our case, the patient used the Internet to find loperamide as a potential form of self treatment for heroin addiction. She was unable to afford methadone maintenance and psychotherapy, which could have prevented her sequence of events. She reported her search strategy of “home remedies, heroin withdrawal” uncovered multiple sites, blogs, and chat rooms describing loperamide use to manage heroin withdrawal symptoms. One blog post claims that loperamide is a “godsend” for patients who cannot afford standard therapy.2 Another forum “highly recommends” using loperamide for opiate withdrawal diarrhea and cramping.3 Another reports that “with loperamide [I] avoided 90% of heroin withdrawal symptoms, with very few complications.”4

The Internet and social media outlets can plant the seed for off-label use of OTC medicines. Loperamide is just 1 example. Although most commonly used for the treatment of diarrhea, loperamide is being used for other reasons including self-management of opioid withdrawal. Misuse of loperamide is associated with potentially serious side effects (cardiac arrhythmias; QT prolongation) and even death.

Notes

  • This article was externally peer reviewed.

  • Funding: none.

  • Conflict of interest: none declared.

  • To see this article online, please go to: http://jabfm.org/content/30/6/832.full.

  • Received for publication February 20, 2017.
  • Revision received June 10, 2017.
  • Accepted for publication June 17, 2017.

References

  1. 1.↵
    U.S. Food & Drug Administration. FDA Drug Saf Communication: FDA warns about serious heart problems with high doses of the antidiarrheal medicine loperamide (Imodium), including from abuse and misuse. Silver Spring, MD, 2016.
  2. 2.↵
    Bluelight. Opioids: Using loperamide to combat methadone withdrawal? Available from: http://www.bluelight.org/vb/threads/623252. Accessed June 9, 2017.
  3. 3.↵
    1. Finch M
    . Opiate Addiction Support. How to use loperamide for opiate withdrawal. January 22, 2015. Available from: https://opiateaddictionsupport.com/how-to-use-loperamide-for-opiate-withdrawal/. Accessed June 9, 2017.
  4. 4.↵
    Bluelight. Opioids: Big and dandy loperamide addiction thread. 2012. Available from: http://www.bluelight.org/vb/threads/440234. Accessed June 9, 2017.
  5. 5.↵
    1. Naranjo CA,
    2. Busto U,
    3. Sellers EM,
    4. et al
    . A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239–245.
    OpenUrlCrossRefPubMed
  6. 6.↵
    World Health Organization. WHO Model List of Essential Medicines, 20th List. 2017. Available from: http://www.who.int/medicines/publications/essentialmedicines/en/.
  7. 7.↵
    Mylan Pharmaceuticals, Inc. Loperamide hydrochloride [prescribing information]. Morgantown, WV: Mylan Pharmaceuticals, Inc.; Oct 2016.
  8. 8.↵
    1. Awouters F,
    2. Megens A,
    3. Verlinden M,
    4. Schuurkes J,
    5. Niemegeers C,
    6. Janssen PA
    . Loperamide. Survey of studies on mechanism of its antidiarrheal activity. Digest Dis Sci 1993;38:977–995.
    OpenUrl
  9. 9.↵
    1. Marraffa JM,
    2. Holland MG,
    3. Sullivan RW,
    4. et al
    . Cardiac conduction disturbance after loperamide abuse. Clin Toxicol 2014;52:952–957.
    OpenUrlCrossRef
  10. 10.↵
    1. Eggleston W,
    2. Clark KH,
    3. Marraffa JM
    . Loperamide abuse associated with cardiac dysrhythmia and death. Ann Emerg Med 2017;69:83–86.
    OpenUrl
  11. 11.↵
    1. Mukarram O,
    2. Hindi Y,
    3. Catalasan G,
    4. Ward J
    . Loperamide induced torsades de pointes: A case report and review of the literature. Case Rep Med 2016;2016:4061980.
    OpenUrl
  12. 12.↵
    1. Lasoff DR,
    2. Schneir A
    . Ventricular dysrhythmias from loperamide abuse. J Emerg Med 2016;50:508–509.
    OpenUrl
PreviousNext
Back to top

In this issue

The Journal of the American Board of Family     Medicine: 30 (6)
The Journal of the American Board of Family Medicine
Vol. 30, Issue 6
November-December 2017
  • Table of Contents
  • Table of Contents (PDF)
  • Cover (PDF)
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on American Board of Family Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Dysrhythmias with Loperamide Used for Opioid Withdrawal
(Your Name) has sent you a message from American Board of Family Medicine
(Your Name) thought you would like to see the American Board of Family Medicine web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
7 + 7 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Dysrhythmias with Loperamide Used for Opioid Withdrawal
Nicki D. Vithalani, Christopher Heron, Ravishankar E. Rao, Anthony F. Cardell, Mark B. Stephens
The Journal of the American Board of Family Medicine Nov 2017, 30 (6) 832-834; DOI: 10.3122/jabfm.2017.06.170066

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Dysrhythmias with Loperamide Used for Opioid Withdrawal
Nicki D. Vithalani, Christopher Heron, Ravishankar E. Rao, Anthony F. Cardell, Mark B. Stephens
The Journal of the American Board of Family Medicine Nov 2017, 30 (6) 832-834; DOI: 10.3122/jabfm.2017.06.170066
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Case Presentation
    • Discussion
    • Notes
    • References
  • Figures & Data
  • References
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • Re: Dysrhythmias with Loperamide Used for Opioid Withdrawal
  • Multiple Practical Facts and Ideas to Improve Family Medicine Care
  • Google Scholar

More in this TOC Section

  • Factors Influencing Changing Scopes of Practice Among Contemporary Graduates of the Nation’s Largest Family Medicine Residency
  • Association of Social Needs with Diabetes Outcomes in an Older Population
  • Patient Perspectives on Delayed Specialty Follow-Up After a Primary Care Visit
Show more Brief Reports

Similar Articles

Keywords

  • Cardiovascular System
  • Community Medicine
  • Loperamide
  • Opioids
  • Patient Care
  • Primary Health Care
  • Substance Withdrawal Syndrome
  • Torsades de Pointes
  • Toxicity

Navigate

  • Home
  • Current Issue
  • Past Issues

Authors & Reviewers

  • Info For Authors
  • Info For Reviewers
  • Submit A Manuscript/Review

Other Services

  • Get Email Alerts
  • Classifieds
  • Reprints and Permissions

Other Resources

  • Forms
  • Contact Us
  • ABFM News

© 2025 American Board of Family Medicine

Powered by HighWire